Clinical outcome of patients with childhood acute lymphoblastic leukaemia and an initial leukaemic blood blast count of less than 1000 per microliter

被引:26
作者
Lauten, M [1 ]
Stanulla, M [1 ]
Zimmermann, M [1 ]
Welte, K [1 ]
Riehm, H [1 ]
Schrappe, M [1 ]
机构
[1] Childrens Hosp, Hannover Med Sch, Dept Paediat Haematol & Oncol, D-30625 Hannover, Germany
来源
KLINISCHE PADIATRIE | 2001年 / 213卷 / 04期
关键词
leukaemia; leukemia; ALL; childhood; prednisone response; prognosis; event free survival; treatment response;
D O I
10.1055/s-2001-16848
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Background: One of the strongest predictive factors for therapy outcome in childhood acute lymphoblastic leukaemia (ALL), treated according to ALL-BFM protocols, is the response to initial prednisone treatment. Prednisone response is characterized by the peripheral leukaemic blast count. The threshold value for the characterisation as good or poor prednisone response is 1000 blasts/mul on day eight of initial prednisone treatment. It is frequently being discussed, whether patients with ALL that initially present with < 1000 blasts/mul and still show < 1000 blasts/mul by day eight of treatment, have the same therapy outcome as prednisone good-responders with initially greater than or equal to 1000 blasts/mul. Patients and methods: We evaluated all patients included in the ALL-BFM 90 study showing good prednisone response. This group included 660 patients presenting with < 1000 blasts/mul at diagnosis. We compared these patients with the prednisone good-responders that initially presented with greater than or equal to 1000 blasts/mul. In addition we analysed all patients who showed an increasing blast count within the threshold of 1000 blasts/mul by day eight of treatment. Results: Children presenting with ALL and < 1000 blasts/mul at diagnosis showed a small but significantly better outcome than prednisone good-responders with initially greater than or equal to 1000 blasts/mul (5 year pEFS 0.86 vs. 0.81, P value 0.0064). If analyzed by treatment group, no significant differences were found. Patients with < 1000 blasts/mul on day eight of treatment but increasing blast count from diagnosis until day eight did not perform worse. Conclusion: The prognostic value of the prednisone response is not restricted to childhood ALL patients presenting with < 1000 blasts/mul at diagnosis, but retains its strength as a strong predictor of treatment outcome also in patients with < 1000 blasts/mul at diagnosis.
引用
收藏
页码:169 / 174
页数:6
相关论文
共 19 条
[1]  
ARICO M, 1995, CANCER, V75, P1684, DOI 10.1002/1097-0142(19950401)75:7<1684::AID-CNCR2820750720>3.0.CO
[2]  
2-2
[3]   INTENSIFICATION OF TREATMENT AND SURVIVAL IN ALL CHILDREN WITH LYMPHOBLASTIC-LEUKEMIA - RESULTS OF UK MEDICAL-RESEARCH-COUNCIL TRIAL UKALL-X [J].
CHESSELLS, JM ;
BAILEY, C ;
RICHARDS, SM ;
EDEN, OB ;
BARBOR, PRH ;
BARRETT, A ;
BARTON, C ;
BROADBENT, V ;
DEMPSEY, SI ;
DURRANT, J ;
EMERSON, P ;
EVANS, DIK ;
FENNELLY, JJ ;
GALTON, DAG ;
GIBSON, B ;
GRAY, R ;
HANN, IM ;
HARDISTY, RM ;
HILL, FGH ;
KERNAHAN, J ;
KING, DJ ;
LILLEYMAN, JS ;
MANN, J ;
MARTIN, J ;
MCELWAIN, TJ ;
MELLOR, ST ;
JONES, PHM ;
OAKHILL, A ;
PETO, J ;
RADFORD, M ;
REES, JKH ;
STEVENS, RF ;
SUMMERFIELD, GP ;
THOMPSON, EN .
LANCET, 1995, 345 (8943) :143-148
[4]   Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia [J].
Dördelmann, M ;
Reiter, A ;
Borkhardt, A ;
Ludwig, WD ;
Götz, N ;
Viehmann, S ;
Gadner, H ;
Riehm, H ;
Schrappe, M .
BLOOD, 1999, 94 (04) :1209-1217
[5]   PERSISTENCE OF CIRCULATING BLASTS AFTER 1 WEEK OF MULTIAGENT CHEMOTHERAPY CONFERS A POOR-PROGNOSIS IN CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA [J].
GAJJAR, A ;
RIBEIRO, R ;
HANCOCK, ML ;
RIVERA, GK ;
MAHMOUD, H ;
SANDLUND, JT ;
CRIST, WM ;
PUI, CH .
BLOOD, 1995, 86 (04) :1292-1295
[6]  
Gaynon PS, 1997, CANCER-AM CANCER SOC, V80, P1717, DOI 10.1002/(SICI)1097-0142(19971101)80:9<1717::AID-CNCR4>3.0.CO
[7]  
2-B
[8]   DAY-7 MARROW RESPONSE AND OUTCOME FOR CHILDREN WITH ACUTE LYMPHOBLASTIC-LEUKEMIA AND UNFAVORABLE PRESENTING FEATURES [J].
GAYNON, PS ;
BLEYER, A ;
STEINHERZ, PG ;
FINKLESTEIN, JZ ;
LITTMAN, P ;
MILLER, DR ;
REAMAN, G ;
SATHER, H ;
HAMMOND, GD .
MEDICAL AND PEDIATRIC ONCOLOGY, 1990, 18 (04) :273-279
[9]   NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].
KAPLAN, EL ;
MEIER, P .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481
[10]   Prednisolone resistance in childhood acute lymphoblastic leukemia: Vitro-vivo correlations and cross-resistance to other drugs [J].
Kaspers, GJL ;
Pieters, R ;
Van Zantwijk, CH ;
Van Wering, ER ;
Van der Does-Van den Berg, A ;
Veerman, AJP .
BLOOD, 1998, 92 (01) :259-266